Stay updated with breaking news from Ontract Development Services. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The "North American Healthcare CDMO Market 2020-2026" report has been added to ResearchAndMarkets.com's offering.
Samsung Biologics (KRX: 207940.KS), a leading global CDMO providing end-to-end contract development and manufacturing services, today announced its plans to add mRNA vaccine drug substance (DS) manufacturing capability to the current facility in Songdo, ready for cGMP operations within the earlier part of the year in 2022. mRNA has been the technology of choice for many COVID-19 vaccines due to its characteristics of safety, and fast scalability in manufacturing.